Effects of Dan-Lou Tablet for Coronary Heart Disease Stable Angina Pectoris with Intermingled Phlegm and Blood Stasis Pattern: A Randomized, Double-blinded, Parallel Placebo controlled Trial

Phase 4

Not yet recruiting

• Conditions: Coronary heart disease stable angina pectoris

• Registration Number: ITMCTR1900002839
• Lead Sponsor: Guang'anmen Hospital,Chinese Academy of Traditiona Chinese medicine

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 2023-02-20

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

1. Conform to the diagnosis of coronary heart disease stable angina pectoris with intermingled phlegm and blood stasis Pattern;
2. Between the ages of 30 and 75 years;
3. Volunteer for this event and sign an informed consent form.

Exclusion Criteria

1. Unstable angina pectoris and acute myocardial infarction; other congenital heart disease, valvular disease, severe neurosis caused by chest pain; heart function of grade III or IV; chest pain caused by arrhythmia;
2. Acute stage of cerebral infarction;
3. Complicated with heart, brain, liver, kidney, hematopoietic system and other serious primary diseases abnormal renal function;
4. Acute infection within the last two weeks;
5. Patients with other serious diseases that require treatment;
6. Mental disorders or mental retardation that cannot complete the questionnaire;
7. Pregnant and lactating women;
8. Tendency to bleed, abnormal of DIC or INR, low platelet;
9. Patients who did not participate in other clinical trials within 1 month;
10. Allergic constitution or allergic to test drug ingredient.

Study & Design

• Study Type: Interventional study
• Study Design: Not specified